SOURCE: MMR Information Systems, Inc.

MMR Information Systems, Inc.

April 14, 2010 10:39 ET

MMR Information Systems, Inc. Reaches Agreement With Lymphoma Research Foundation Regarding Study Data and Patient Samples

LOS ANGELES, CA--(Marketwire - April 14, 2010) - MMR Information Systems (OTCBB: MMRF) ("MMR") disclosed today that it has reached agreement with the Lymphoma Research Foundation ("LRF"), under which the two organizations will work in good faith regarding the use of pre-merger Favrille intellectual property for cancer research. The Company acquired this intellectual property and related technology through its reverse merger with Favrille, Inc., a biopharmaceutical company, in January 2009.

MMR has recently discovered the existence of intellectual property in the form of approximately 150 patient samples collected during the Company's Favrille pre-merger vaccine trials. Through May of 2008, pre-merger Favrille had spent more than $140 million on the creation and development of intellectual property, which includes clinical trials data, patient samples, patents and other assets. The Company hopes to enter into licensing agreements with biopharmaceutical companies, academic institutions, research organizations and others regarding the use of the assets.

Based on discussions with biotech consultants and others, MMR understands that the Company's IP may unlock ways to create "custom-made" cancer vaccines and identify other opportunities in cancer research. MMR also understands that these assets could lead to a positive reinterpretation of the results of the Company's previous Favrille vaccine trials.

According to Robert H. Lorsch, MMR Chief Executive Officer, "MMR continues to learn more about its pre-merger Favrille assets and the value they can bring to MMR shareholders and others. We hope that through a relationship with LRF the Company can identify organizations around the world that can put these assets to use in the fight against cancer while generating revenue for MMR shareholders."

Although MMR will continue to maximize the value of these biotech assets to its shareholders, the Company remains focused on its primary business, which is specifically the development and distribution of the MyMedicalRecords Personal Health Record (www.MyMedicalRecords.com) MMRPro, an end-to-end document management solution for physicians which features an integrated patient portal (www.MyMedicalRecordsMD.com), and other related solutions in Health IT based on the Company's patented technologies.

About MMR Information Systems, Inc.
MMR Information Systems, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, unions and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Information Systems, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mymedicalrecordsonline.com/videos.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements regarding the Company's assets including but not limited to its primary Health IT businesses, data from vaccine and clinical trials, and anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the development and approval of biotechnology/biopharmaceutical product candidates and Health IT products and additional risks discussed in the Company's filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company's behalf) are qualified by the cautionary statements in this notice. MMR Information Systems, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information